



Review Article

Folate-biopterin Crosstalk in Human Disease



Mark D. Lucock^{1*} and Robert J. Leeming²

¹School of Environmental & Life Sciences, University of Newcastle, Ourimbah, NSW, Australia; ²Screening Laboratory, Clinical Chemistry Department, Children's Hospital, Birmingham, West Midlands, UK

Received: April 18, 2025 | Revised: May 27, 2025 | Accepted: June 04, 2025 | Published online: July 04, 2025

Abstract

The importance of putative folate-biopterin metabolic interactions lies in the role they may play in the expression of several clinically relevant phenotypes. However, to date, clinical studies on folate-biopterin interactions have been limited. The purpose of this article was to highlight the close relationship between these two cofactors, which share structural similarities and exhibit overlapping metabolic pathways. This folate-biopterin crosstalk has generated several ideas and hypotheses that are critical to advancing the biochemical understanding of several important and seemingly disparate clinical and/or biologically important phenotypes. These phenotypes include melanization/pigmentation, phenylketonuria, autism, neural tube defects, affective disorders, and vascular disease. This review provides a timely, integrated overview of this important area of biochemistry, which is under-represented in the literature and would benefit from further scientific and clinical investigation using improved metabolite-specific analytical methodologies applied to clinically relevant questions.

Introduction

The closely related enzymes dihydrofolate reductase (DHFR; EC 1.5.1.3) and dihydropteridine reductase (DHPR; EC 1.6.99.10) both utilize a reduced dinucleotide cofactor to convert a “dihydro” pteridine residue into a “tetrahydropteridine” product. In the case of DHFR, the substrate is the 7,8-dihydro form of folic acid (H₂PteGlu), while in the case of DHPR, the substrate is a quinonoid dihydrobiopterin (BH₂). The products of these reactions are tetrahydrofolate (H₄PteGlu) and tetrahydrobiopterin (BH₄ [6R-L-erythro-5,6,7,8-tetrahydrobiopterin]), respectively.

Historically, it has been suggested that biopterin and folate co-enzymes can interact in a reciprocal manner, providing utility for biochemical pathways supported by both coenzyme families. For example, BH₂ may be salvaged to BH₄ via DHFR,¹ or via methyl-ene-tetrahydrofolate reductase (MTHFR; EC 1.5.1.20),^{2–4} as well as via the classic DHPR pathway.

The objective of this review was to explore the metabolic interaction between these two cofactor families and to examine how folate-biopterin crosstalk impacts important clinical phenotypes, such as phenylketonuria (PKU), autism, neural tube defect (NTD), vascular disease, and affective disorders, as well as the biologically significant phenotype, skin pigmentation. To achieve this, we

discuss relevant metabolic biomarkers, genetics, therapeutic interventions (including iatrogenesis), and intriguing questions that have emerged from the relatively small body of research published on the folate-biopterin nexus since the 1980s.

This review will provide a brief overview of this key area, which is under-represented in the literature and, in the authors' view, would benefit from further exploration.

General background on cofactor biology

Biopterins

According to Himmelreich and colleagues,¹ BH₄ deficiencies encompass a group of rare inherited neurological disorders characterized by neurotransmitter dysfunction and may or may not include hyperphenylalaninemia.⁵

The reduced pterin, BH₄, is likely to be present in most human tissues, where it acts as an essential cofactor for several enzymes necessary for a diverse range of metabolic processes. It would not be too much of a leap to describe biopterin biochemistry as pleiotropic in nature, given how dependent enzymes such as tyrosine hydroxylase, tryptophan hydroxylases type 1 and 2, phenylalanine hydroxylase, isoforms of nitric oxide synthase 1–3, and alkylglycerol monooxygenase are in maintaining health as well as determining a diverse range of clinical phenotypes.⁶ Furthermore, there is an obligatory need for BH₄ in L-phenylalanine degradation and the biosynthesis of the critical monoamine neurotransmitters dopamine, serotonin, norepinephrine, and epinephrine. It has been established that there is an altered BH₄:neopterin ratio in depression, which might reflect a decreased ability to convert neopterin

Keywords: Biopterin; Folate; Affective disorders; Autism spectrum disorder; Neural tube defect; Skin pigmentation; Vascular disease; Metabolism.

***Correspondence to:** Mark D. Lucock, University of Newcastle, Brush Rd, Ourimbah, NSW 2258, Australia. ORCID: <https://orcid.org/0000-0002-0788-5177>. Tel: +61-2-4348-4109, E-mail: mark.lucock@newcastle.edu.au

How to cite this article: Lucock MD, Leeming RJ. Folate-biopterin Crosstalk in Human Disease. *Explor Res Hypothesis Med* 2025;000(000):000–000. doi: 10.14218/ERHM.2025.00020.




Fig. 1. Metabolic pathways of folate and biopterin: key enzymes and interactions. Numerical key to enzymes shown in a generalized metabolic pathway for the biopterin–folate nexus. 1: GTP cyclohydrolase; 2: 6-pyruvoyl-tetrahydropterin synthase; 3: carbonyl reductase; 4: sepiapterin reductase; 5: 3β-hydroxysteroid dehydrogenase 2; 6: aldose reductase; 7: dihydropteridine reductase; 8: pterin-4α-carbinolamine dehydratase; 9: phenylalanine hydroxylase; 10: tyrosine hydroxylase; 11: tryptophan hydroxylase type 1; 12: tryptophan hydroxylase type 2; 13: DNAJ heat shock protein family member C12; 14: dihydrofolate reductase; 15: methionine synthase; 16: methionine synthase reductase; 17: methylenetetrahydrofolate reductase; 18: serine hydroxymethyltransferase; 19: thymidylate synthase; 20: methylenetetrahydrofolate dehydrogenase1; 21: methylenetetrahydrofolate cyclohydrolase; 22: formyltetrahydrofolate synthetase. DNAJ, member of the heat shock protein molecular chaperones, also called J-protein family; dTMP, thymidine monophosphate; dUMP, deoxyuridine monophosphate; GTP, guanosine triphosphate; NO, nitric oxide.

to BH_4 .^{4,7–9} There is also a loose connection between BH_4 and chronic pain sensitivity,¹⁰ as well as modulating T cell proliferation in autoimmunity and cancer.¹¹ BH_4 also enhances nitric oxide-dependent vasodilation in human skin through endothelial nitric oxide synthase (eNOS)-coupling mechanisms.¹²

BH_4 deficiencies may be linked to a variety of gene polymorphisms. Himmelreich and colleagues report on 800 variants and summarize the genetic basis, phenotypic presentation, and functional consequences linked to BH_4 deficiencies.¹

Figure 1 provides a generalized metabolic pathway for the biopterin–folate nexus.

Folates

Folate in the diet is either native 5-methyltetrahydrofolate ($5\text{CH}_3\text{-H}_4\text{PteGlu}$) or synthetic provitamin pteroylmonoglutamic acid (PteGlu). Up to an oral dose of around 266–400 μg of PteGlu, bioconversion to $5\text{CH}_3\text{-H}_4\text{PteGlu}$ is highly efficient. However, above this level of intake, unmetabolized PteGlu appears in the blood plasma.^{13,14} Despite the wide adoption of mandatory folate fortification to prevent NTD, concerns exist over the possible consequences of excessive exposure to provitamin PteGlu.¹⁵ The natural plasma (and cerebrospinal fluid (CSF)) form of the vitamin is $5\text{CH}_3\text{-H}_4\text{PteGlu}$. This is the “transport” form and is a monoglu-

tamyl vitamer. Once it is translocated into the cell, it must be demethylated and converted into a polyglutamyl coenzyme before it can be used as a cofactor in one-carbon transfer metabolism (folyl-polyglutamates exhibit lower K_m values and hence greater affinity for their dependent enzymes).

The critically important metabolic roles of folate are manifold, and like biopterin, it plays an important role in maintaining health and determining a diverse range of clinical phenotypes, indeed, probably more so than biopterin. It is responsible for the biosynthesis of purine, pyrimidine, and methionine, as well as the interconversion of glycine and serine. Additionally, it is needed for histidine catabolism.¹⁶ It's fair to say that the biochemical pathways most likely to link folate to phenotype are DNA–thymidylate (dTMP) biosynthesis and *de novo* methionine production, which is used for both genomic (CpG [cytosine nucleotide followed by guanine nucleotide]) and non-genomic methylations.¹⁷

In folate depletion, uracil is misincorporated into the primary DNA base sequence in place of thymine, leading to DNA fragility.¹⁸ The critical nature of folates in determining phenotype is further exemplified by the propagation of *de novo* methionine biosynthesis by $5\text{CH}_3\text{-H}_4\text{PteGlu}$, which supplies methyl groups to the methylome and thus governs gene expression—half our methionine requirement is met via this route.^{19,20} Furthermore, folate vitamers act as coenzymes fueling *de novo* synthesis of purine nu-

cleotides. As part of the purine cycle, the C-8 and C-2 positions within the purine ring stem from 10-formyltetrahydrofolate via reactions catalyzed by glycineamide ribonucleotide transformylase and 5-amino-4-imidazolecarboxamide ribonucleotide transformylase. These enzymes convert glycineamide ribonucleotide into formyl-glycineamide ribonucleotide and aminomidazole carboxamide ribonucleotide into formyl-aminoimidazole carboxamide ribonucleotide, respectively.¹⁶

Figure 1 provides a generalized metabolic pathway for folic acid-related one-carbon transfers.

Bringing the pathways together

This article aimed to inform and raise important questions regarding the overlap between folate and biopterin metabolism and phenotypic expression. Both reduced folates and biopterin are extremely sensitive to oxidation, and it has been suggested that folate is critical in the regeneration of labile BH₄. While the antioxidant properties of reduced folates may be relevant, the primary mechanism for BH₄ regeneration appears to involve a salvage pathway mediated by DHFR.²¹ A further biochemical overlap occurs in the form of eNOS, the enzyme responsible for generating nitric oxide in vascular endothelial cells, with BH₄ as its obligate cofactor. Notably, 5CH₃-H₄PteGlu has been shown to regenerate oxidized BH₂ to reduced BH₄.²² This reduced folate coenzyme can also substitute for BH₄ at the enzyme cofactor level.²³ If this finding is correct, it suggests that the molecular structures of BH₄ and 5CH₃-H₄PteGlu are sufficiently similar that eNOS can accept 5CH₃-H₄PteGlu as a substitute cofactor.^{4,24} However, it remains unclear whether reduced folates can also substitute for BH₄ in the hydroxylase enzymes involved in monoamine neurotransmitter synthesis, as they do with eNOS.⁴ Indeed, it is the author's view that CSF 5CH₃-H₄PteGlu provides a valuable source of methyl groups to support biogenic amine biosynthesis, likely representing the primary mechanism by which folate modulates monoamine neurotransmitter levels and mood disorders.²⁵

Table 1 summarizes key clinical and experimental (animal and cell culture) evidence supporting the folate/biopterin cofactor nexus.^{2,3,21-24,26-42}

Genes of putative relevance in the folate-biopterin nexus

Five major genes involved in biopterin metabolism exist in variant form and elicit coding and phenotypic effects. These include *GCH1* (324 variants), *PTS* (199 variants), *SPR* (104 variants), *PCBD* (32 variants), and *QDPR* (141 variants). These genes encode the following proteins: GTP cyclohydrolase I feedback regulatory protein, 6-pyruvoyl-tetrahydropterin synthase, sepiapterin reductase, pterin-4 α -carbinolamine dehydratase, and quinoid DHPR, respectively. The biochemical orchestration of this area of metabolism is shown in Figure 1.

Folate metabolism is somewhat more complex, with a broader and deeper metabolic influence. Folyl vitamers serve as coenzymes for life-critical biosynthetic pathways, including those feeding the epigenome (methylome), generalized methylations (e.g., neurotransmitters), and nucleotide biosynthesis required for DNA elaboration. These folate-dependent pathways are critical for both short- and long-term phenotypic adaptation or maladaptation and, as such, contribute to the development of several early-life developmental and later-life degenerative disorders.⁴³ Important coenzymes include H₂PteGlu, H₄PteGlu, 5CH₃-H₄PteGlu, 5,10CH₂-H₄PteGlu, 10CHO-H₄PteGlu, and 5,10CH-H₄PteGlu, which exist in both mono- and polyglutamate forms. Some of the most critical enzymes for these cofactors include: methionine synthase (rs1805087), methionine

synthase reductase (rs1801394), MTHFR (rs1801133, rs1801131), serine hydroxymethyltransferase (rs1979277), thymidylate synthase (rs34489327, rs45445694), DHFR (rs70991108), reduced folate carrier (rs1051266), and methylenetetrahydrofolate dehydrogenase (rs2236225, rs1950902). Although MTHFR and DHFR are the most obvious candidates for interaction/overlap with biopterin metabolism, it is important to note that, due to the tight integration of one-carbon transfers, some of the most phenotypically significant folate-related gene polymorphisms are listed in square brackets for each of the listed folate enzymes. The biochemical orchestration of this area of metabolism is shown in Figure 1.

Insights and questions on the folate-biopterin metabolic nexus

In 2006, Leeming and Hall suggested that DHPR plays a key role in folate metabolism in the central nervous system (CNS),²⁶ as evidenced by low concentrations of folate species in the CSF and blood of patients with DHPR deficiency. Furthermore, for reasons that remain unclear, CSF folate concentrations are further reduced by the administration of the provitamin, PteGlu, although peripheral total folate concentrations normalize. A key observation here is that the clinical condition deteriorates significantly with synthetic PteGlu, whereas it improves following administration of natural 5-formyltetrahydrofolic acid (hereinafter referred to as 5CHO-H₄PteGlu).²⁷ In DHPR deficiency, it is well recognized that there is an increase in 7,8-dihydrobiopterin/BH₂ in the peripheral circulation, similar to what occurs in classic PKU (phenylalanine hydroxylase deficiency), where significant perturbation of folate metabolism is also observed.²⁸

The exact role of DHPR in folate metabolism remains unclear, although normal salvage of quinoid BH₂ (and possibly partially oxidized folates) appears to require both pterin-4 α -carbinolamine dehydratase (PCD) and DHPR. When PCD is inactive, a transient hyperphenylalaninemia occurs, which does not require treatment, but 7-substituted forms of biopterin and neopterin are produced.⁴⁴ Based on these observations, Leeming and Hall suggest it would be valuable to investigate these rare cases further to see whether 7-folates are also generated, as this would point to a direct role for this salvage pathway in folate metabolism.

In 2010, the same authors reiterated that the role of DHPR in folate metabolism has never been experimentally proven.²⁹ However, they emphasized that there is little evidence in the literature to suggest that DHFR is present in the human brain to any significant extent.³⁰ If DHFR is relatively scarce in the brain, DHPR almost certainly plays a major role in maintaining the various reduced folate coenzyme pools.³⁰ It is recognized that CSF 5CH₃-H₄PteGlu is present at levels two to three times higher than in blood plasma,⁴⁵ suggesting active transport at the choroid plexus.

Following the administration of provitamin PteGlu, the low concentrations of CSF 5CH₃-H₄PteGlu in DHPR-deficient individuals drop to catastrophically low levels, leading to substantial physical changes in the brain.²⁷ It has been suggested that in DHPR deficiency, following PteGlu administration, the CSF 5CH₃-H₄PteGlu deficit arises due to a build-up of BH₂, which is also a substrate for the DHFR salvage pathway, whose normal substrate is H₂PteGlu. The hypothesis is that BH₂ accumulation could compete/interfere with normal folate-dependent one-carbon metabolic flux, specifically the catalytic conversion of PteGlu to H₂PteGlu (high Km), and subsequently to H₄PteGlu (low Km). Despite this hypothesis, other situations exist where BH₂ is markedly elevated without any obvious implications for CSF/folate levels. One example is PKU,⁴⁶ which, although having broader effects on peripheral

Table 1. Selected key evidence supporting the folate–biopterin metabolic nexus

Authors	Research relevance	Research model
Shi <i>et al.</i> , 2004 ²⁴	Epiphenomenal folate and vitamin C enhances BH ₄ bioavailability contributing to endothelial homeostasis	Key review
Hasegawa <i>et al.</i> , 2005 ²¹	Elevation in BH ₄ by supplementation is via a “salvage pathway” that included BH ₂ as the key intermediate in production of BH ₄ through the action of DHFR	Cell culture and mouse model
Antoniades <i>et al.</i> , 2006 ²²	5CH ₃ -H ₄ PteGlu has a beneficial impact on endothelial function and vascular superoxide synthesis in human atherosclerosis. This is achieved via inhibition of peroxynitrite-mediated BH ₄ oxidation and enhanced eNOS coupling	Human study
Hyndman <i>et al.</i> , 2002 ²³	5CH ₃ -H ₄ PteGlu attenuates superoxide production (induced by inhibition of BH ₄ synthesis) and improves endothelial function in rat aortae isolated from BH ₄ -deficient rats. Therefore, 5CH ₃ -H ₄ PteGlu interacts with nitric oxide synthase to promote production of nitric oxide and improve endothelial function	Isolated rat aortae
Matthews <i>et al.</i> , 1980 ³	Pig liver MTHFR catalyzes reduction of quinonoid BH ₂ <i>in vitro</i>	Pig liver model
Kaufman, 1991 ²	MTHFR can use 5CH ₃ -H ₄ PteGlu to regenerate BH ₄ from quinonoid BH ₂ which may thus provide an escape from the putative “methyl trap”	Review
Leeming <i>et al.</i> , 2006 ²⁶ and Smith <i>et al.</i> , 1985 ²⁷	Low concentrations of folate vitamers occur in the CSF and blood of patients with DHPR deficiency. Symptoms deteriorate with synthetic folic acid but improve with leucovorin (5CHO-H ₄ PteGlu)	Research letter based on clinical evidence and human study
Lucock <i>et al.</i> , 2002 ²⁸	PKU patients have an altered distribution of blood folate vitamers supporting that biopterin and folate pathways may interact	Human study
Pollack <i>et al.</i> , 1978 ³⁰	DHPR helps preserve tetrahydrofolate from oxidation in brain tissue. Substantially lower folate levels are found in brain biopsies from humans lacking DHPR supporting a role for this biopterin enzyme in folate metabolism	Human study
Leeming <i>et al.</i> , 2010 ²⁹ and Smith <i>et al.</i> , 1985 ²⁷	Following administration of synthetic PteGlu, already low levels of CSF 5CH ₃ -H ₄ PteGlu in DHPR deficient patients falls to extremely low levels and is linked to physical changes in the brain	Research letter based on clinical evidence and human study
Leeming <i>et al.</i> , 1976 ³¹	The antifolate, methotrexate, increases serum biopterin levels, which increase even further following administration of both synthetic folic acid and 5-CHO-H ₄ PteGlu. This contrasted with a total absence of response to oral folates without prior methotrexate	Human study
Wolf <i>et al.</i> , 2018 ³²	Acute UV-B radiation exposure attenuates biopterin dependent NO-mediated vasodilation of the cutaneous microvasculature via degradation of 5CH ₃ -H ₄ PteGlu	Human study
Blau <i>et al.</i> , 2001 ³³	Despite humans being unable to synthesise folate <i>de novo</i> , bacteria can. GTP cyclohydrolase 1 is used by bacteria for folate production, but is also used by humans for BH ₄ biosynthesis	Human context
Bottiglieri <i>et al.</i> , 1992 ³⁴	CSF levels of BH ₄ are significantly correlated to monoamines and red cell folate	Human study
Smith <i>et al.</i> , 1986 ³⁵	Patients with DHPR insufficiency accumulate BH ₂ and develop secondary folate deficiency resembling that occurring in subjects with a defective MTHFR activity. In DHPR deficiency cerebral calcification may develop as seen in congenital folate malabsorption and methotrexate toxicity. Symptoms are ameliorated by therapy with 5-formyltetrahydrofolate but exacerbated by folic acid	Human study
Crabtree <i>et al.</i> , 2011 ³⁶	Supplementary to key roles in folate metabolism, DHFR can regenerate BH ₄ from BH ₂ . Thus, it is likely that net BH ₄ cell bioavailability reflects the equilibrium between <i>de novo</i> BH ₄ synthesis, oxidative loss to BH ₂ , and the regeneration of BH ₄ by the reductive folate enzyme, DHFR	Review using multiple model systems
Dickinson <i>et al.</i> , 2024 ³⁷	5CH ₃ -H ₄ PteGlu has a critical role in endothelial cell function in pregnancy. This is related to endothelial cell BH ₄ availability and NO synthase activity. 5CH ₃ -H ₄ PteGlu may be a novel therapeutic agent with potential to improve endothelial function in pregnancy hypertension by targeting endothelial cell BH ₄	Human and mouse study
Chuaiphichai <i>et al.</i> , 2023 ³⁸	Targeting vascular GCH1 and BH ₄ biosynthesis with reduced folates identifies a novel therapeutic target for the prevention and treatment of pregnancy induced hypertension	Mouse model

(continued)

Table 1. (continued)

Authors	Research relevance	Research model
Liu <i>et al.</i> , 2022 ³⁹	Reduced BH ₄ levels promote peroxynitrite formation and aortic valve calcification. Dietary folate attenuates aortic valve calcification by salvaging BH ₄ bioavailability	Mouse model
Maletic <i>et al.</i> , 2023 ⁴⁰	5CH ₃ -H ₄ PteGlu may mitigate depression by driving synthesis of BH ₄ , a critical coenzyme in neurotransmitter production	Human study
Zhilyaeva <i>et al.</i> , 2022 ⁴¹	In a schizophrenia group, BH ₄ and folate levels were lower ($p = 0.001$ and $p = 0.054$, respectively), and the levels of homocysteine were higher ($p = 0.012$) compared to a control group. BH ₄ levels positively correlated with folate ($p = 0.0029$)	Human study
Chalupsky <i>et al.</i> , 2015 ⁴²	Folate upregulation of DHFR recouples eNOS in hypoxia. This is achieved by improved BH ₄ recycling and may have a role in preventing pulmonary hypertension	Human cell model

CSF, cerebrospinal fluid; DHFR, dihydrofolate reductase; eNOS, endothelial nitric oxide synthase; GCH1, gene for GTP cyclohydrolase enzyme; GTP, guanosine triphosphate; MTHFR, methylenetetrahydrofolate reductase; NO, nitric oxide; PKU, phenylketonuria; UV-B, ultraviolet B radiation.

folate status, does not show similar issues in the CSF.²⁸ There are also several iatrogenic causes, and as mentioned earlier, quinonoid BH₂ may interact with the important allosteric MTHFR enzyme. However, how any impact on CNS MTHFR would translate into low CSF 5CH₃-H₄PteGlu remains unclear. If, as previously suggested, DHPR plays a more dominant role in the brain than DHFR, while outside of the CNS, DHFR plays the dominant role, then in DHFR deficiency, is it possible that a) unmetabolized PteGlu competes with reduced folate at DHFR in the liver and residual DHPR activity in a variety of tissues,⁴⁷ and b) impacts active uptake of 5CH₃-H₄PteGlu in the choroid plexus.²⁹ Therefore, in DHPR deficiency, CSF 5CH₃-H₄PteGlu that passes through the blood-brain barrier, once metabolized, cannot be recycled to a reduced state in the absence of both DHFR and DHPR activity, leading to a decline in CSF folate. Vitamin B₁₂ and gene polymorphisms may also contribute to this scenario. Overall, when provitamin PteGlu is administered, replenishment of the critical reduced 5CH₃-H₄PteGlu supply to the brain may be restricted, and the consequences could be catastrophic.

Emphasizing the interconnected role of these two enzymes, early work by Leeming and colleagues demonstrated that the administration of the antifolate drug methotrexate raised serum bipterin levels.³¹ These bipterin levels increased further following the administration of folate (PteGlu and 5-CHO-H₄PteGlu). This contrasted with the total absence of response to oral folates without prior methotrexate treatment and to 5CH₃-H₄PteGlu, whether or not methotrexate was administered. The rationale for this was unclear, and the authors reasonably claimed that little is known about the metabolism of bipterin derivatives in humans, lending further justification to the present article. Despite this, considerable work has been done since these early studies, and the next section explores the impact of these folate/bipterin loci on important phenotypic outcomes.

Focus on important phenotypic outcomes linked to folate and bipterin loci

The following examples are not intended to be comprehensive but instead focus attention on a selection of specific, important phenotypic outcomes.

Mood disorders

Twenty-five percent of US citizens will suffer from depression at some point in their lives. One-third of people with depression have an overt folate deficiency,⁴ while CSF levels of BH₄ are signifi-

cantly correlated with monoamine neurotransmitters and red blood cell folate in depression.²⁸ An interesting point is that both folate and bipterin help direct the biosynthesis of the monoamine neurotransmitters serotonin, epinephrine, and dopamine. The critical form of folate is 5CH₃-H₄PteGlu, which is required for the remethylation of the amino acid metabolite homocysteine, generating methionine, and subsequently S-adenosylmethionine (SAM). SAM mediates numerous biochemical methyl donor reactions, including those leading to the synthesis of the monoamine neurotransmitters. Both SAM and 5CH₃-H₄PteGlu supplementation/therapy can improve mood disorders.^{4,25} Despite this, it remains unclear whether 5CH₃-H₄PteGlu has a direct effect on SAM and, hence, monoamine neurotransmitters, or whether it oxidatively stabilizes, enhances synthesis of, or substitutes for BH₄, which is itself critical in monoamine neurotransmitter biosynthesis.⁴

Autism spectrum disorder (ASD)

The authors have previously raised the question of whether BH₄ could be implicated in autism, and whether this might be relevant to any putative relationship between folate and the patho-aetiology of autism.⁴⁸

As mentioned above, BH₄ and 5CH₃-H₄PteGlu are both critical components in the synthesis of the neurotransmitters dopamine and serotonin, which are relevant to many pathways reported as abnormal in ASD.⁴⁸

Clearly, the relationship between folate and BH₄ in neurological function is interesting, and any perturbation could have significant consequences during development.^{29,31,48} Consider that both urinary and CSF bipterin levels are known to be altered in autistic children, and treatment with BH₄ appears to be beneficial.⁴⁹ Given these observations, the current authors wonder if there could be any adverse interactions between synthetic provitamin PteGlu and bipterin at the level of either DHPR and/or DHFR during embryonic/fetal development. Indeed, it has been shown that several folate gene variants act as risk factors for ASD, including genes encoding both DHFR and MTHFR.^{50–52}

The authors have previously put forward an argument for environmental modulation of photolabile or photosynthetic vitamins mediating autism risk via a complex downstream interaction of genetic/epigenetic phenomena. This provides an explanation for seasonality in this and other developmentally originated disorders.⁴⁸ We believe this is one of the few unifying hypotheses that fully explains ASD and related developmental conditions. It fits with a putative central role for both folate and bipterin metabolism in the patho-aetiology of the condition.

In 2022, the Australian Bureau of Statistics estimated that 1.1% of Australians had autism (1.6% of males and 0.7% of females). Geographically, figures vary, although globally, the World Health Organization suggests that about 1% of children have autism. However, chronologically statistics are also changing, with 2001 figures showing that 0.6% of children had the condition at that time.⁵⁰

Biopterin excess in PKU, and insufficiency in biopterin deficiency disorders

Several individual phenotypes are associated with variants in specific genes within the BH₄ biosynthetic or recycling metabolic pathways. This is clearly mapped out in an article by Himmelreich *et al.*,¹ which identifies various genotype-phenotype relationships. While hyperphenylalaninemia likely leads to an excess of BH₄ in PKU patients, BH₄ deficiency phenotypes require a different approach depending on the severity of the condition. Treatment typically involves a phenylalanine-restricted diet for PKU, and in BH₄ insufficiency, clinical management may include the supplementation of L-dopa and 5-hydroxytryptophan (in addition to the decarboxylase inhibitor carbidopa). These are dopamine and serotonin precursors, combined with sapropterin dihydrochloride, a synthetic analogue of BH₄.^{1,53} Furthermore, 5CHO-H₄PteGlu (folinic acid/leucovorin) is also administered in case of a potential DHPR deficiency, a condition that would lead to low CSF 5CH₃-H₄PteGlu (see earlier).

PKU has a global prevalence of approximately one in 23,930 live births, with around 0.45 million individuals affected globally, and many other gene-related biopterin disorders have similar prevalence rates.¹

NTD

The clinical role of folic acid in the prevention of NTDs is well established, although the precise vitamin-related molecular mechanism remains unclear. The pioneering studies of Dick Smithells in Leeds were the first to demonstrate prevention. His team showed a reduction in the recurrence rate of NTD following periconceptional folic acid-containing multivitamin supplementation.⁵⁴ In 2023, 69 countries had mandatory folic acid fortification in place, 47 had voluntary fortification, and 77 countries had no fortification.⁵⁵ It was found that among 75 countries, the average NTD prevalence (mean [95% confidence interval]) per 10,000 population was 4.19 (4.11–4.28) in countries with mandatory fortification, 7.61 (7.47–7.75) in countries with voluntary fortification, and 9.66 (9.52–9.81) in countries with no fortification.⁵⁵ Several folate genes are also thought to be relevant. As mentioned above, the variant form of MTHFR (C677T-*MTHFR*) is aetiologically significant in autism⁵²; however, it is also a known risk factor for NTDs and is thus considered critical during the earliest phases of the human lifecycle.⁵⁶

Since plasma BH₄ bioavailability has been suggested as a teratogenic factor in the occurrence of NTDs,⁵⁷ Lupo and colleagues identified a specific biopterin gene relevant to NTDs. GCH1 catalyzes the first and rate-limiting step of de novo BH₄ synthesis. A three-polymorphism haplotype in *GCH1* (rs8007267, rs3783641, and rs10483639) modulates *GCH1* gene expression levels, influencing plasma BH₄ bioavailability. The study found that offspring carrying two copies of haplotype C-T-C had a significantly increased NTD risk, while mothers carrying two copies of haplotype C-T-C had a significantly increased risk of having an NTD-affected offspring. This suggests that offspring and maternal variation in the *GCH1* gene may contribute to NTD risk, possibly

via altered BH₄ biosynthesis. Like autism, NTDs demonstrate a clear photoperiodicity. Environmental and genetic factors, along with overlapping biochemistry, must all contribute to these developmental disorders. Despite a huge effort, precise mechanisms remain elusive.

Skin pigmentation phenotype

Skin pigments based on melanin are derived from tyrosine and are synthesized in epidermal melanosomes. These structures are translocated to nearby keratinocytes via transport along dendritic projections. This group of darkly pigmented macromolecular pigments (5,6-dihydroxyindole eumelanin, 5,6-dihydroxyindole-2-carboxylic acid eumelanin, and pheomelanin, *in order of decreasing darkness*) are a variety of biopolymers that are very effective at masking us from harmful ultraviolet radiation (UVR). The process of melanogenesis is regulated by both ion transport and the availability of key precursor substrates. BH₄-dependent phenylalanine hydroxylase transforms phenylalanine into tyrosine in the cytoplasm of the melanocyte. Rate-limiting tyrosine is subsequently transported into the melanosome, where it is transformed into L-DOPA by tyrosine hydroxylase (isoform 1). L-DOPA then activates tyrosinase (TYR), initiating melanogenesis. The activity of TYR is regulated by BH₄ through the formation of a 1:1 inhibitory complex (BH₄:TYR). This complex can be reversed by α - and β -melanocyte-stimulating hormone (MSH), rendering the TYR enzyme active once again. Interestingly, interferon regulatory factor 4 (IRF4) cooperates with the melanocyte master regulator to activate TYR, and it has recently been demonstrated that the *IRF4* pigmentation gene interacts with UV radiation to influence red cell folate levels.^{58,59} Thus, folate and biopterin come together once again in expressing an important phenotype.

There is a more direct link between folate and BH₄ in general, and in the context of the pigmentation phenotype. Along with folate-dependent one-carbon transfers allowing biosynthesis of dTMP (DNA) and methionine (methyl groups, including genomic CpG groups), folate is also needed for purine biosynthesis, including GTP and, hence, the GTP biochemical product, BH₄. Clearly, the relationship between biopterin and folate is deeply entrenched, particularly in the synergistic contribution they make to melanogenesis. Indeed, in a 2022 article,⁵⁹ the present author postulated that since folate is required for BH₄ and thus melanin production, a low folate (a UV-labile vitamin) may equate to a lowered BH₄ status and hence reduced melanin biosynthesis. It was suggested that such a reduction in melanin would lead to even more UVR-related folate loss and hence ever greater DNA damage. This propagates an ongoing negative spiral in folate status, as the low folate levels that do exist will be redirected to DNA repair, and demonstrates how dietary antioxidant status (vitamin C/E/beta-carotene, etc.) is likely relevant in this scenario for protecting reduced and highly labile folates from UV radiation-related oxidation. Folate gene and pigmentation gene interactions are also likely important in modulating this progressive negative spiral in folate status.^{58,59} Even prior to this hypothesis, it had been established and accepted that the degree of melanization is associated with protection against systemic oxidative stress.⁶⁰

Vascular disease

A specific cluster of folate-related genes operates in tight synergy and is critical for dTMP and, hence, DNA biosynthesis. This cluster of genes is potentially polymorphic, making them of interest from a disease risk perspective. However, in the present context, since they aid balanced partitioning of one-carbon units between

dTMP and *de novo* methionine synthesis, they can modulate the level of potentially vasculotoxic homocysteine.⁶¹ This important gene cluster encodes serine hydroxymethyltransferase 1, thymidylate synthase, and DHFR, and is responsible for the utilization of 5,10CH₂-H₄PteGlu for the synthesis of dTMP and, hence, DNA. Linked to this, MTHFR provides an alternative fate for 5,10CH₂-H₄PteGlu, namely reduction to 5CH₃-H₄PteGlu and utilization for the conversion of homocysteine into methionine, a process that also requires vitamin B₁₂. This critical metabolic locus provides a fork in the road for one-carbon units, with gene variation altering the probability of which metabolic route one-carbon units will take. It seems reasonable to assume that the nature of the “metabolic/genetic wiring” at this location will interact with dietary folate/folate status, UV exposure, and other exposomal factors to influence levels of vasculotoxic homocysteine, DNA synthesis, biopterin, and other cognate metabolites. In doing so, it will modify the risk for vascular disease, as well as other conditions, including cancer and birth defects.

There is also a more direct link between folate and biopterin in the context of vascular disease, as touched upon earlier. It is believed that reduced folate (5CH₃-H₄PteGlu) interacts with biopterin metabolism directly and/or via an antioxidative effect and thereby influences nitric oxide synthesis, affecting vascular health.^{32,62} Nitric oxide, or endothelium-derived relaxing factor, is a vasodilator released by endothelial cells that line blood vessel walls; it relaxes vascular smooth muscle and inhibits platelet aggregation. For cardiovascular diseases as a whole, the World Health Organization estimates that 17.9 million lives are lost each year, making this cofactor nexus a potentially important area for therapeutic intervention.

In considering the complexity and importance of folate and biopterin cofactors in the above contexts, it is also important to recognize that folate and biopterin may also interact via structural similarity, although this remains to be proven.²⁸

Study limitations

The main issue is that few human studies on this area of metabolism have been carried out over the last 20 years. However, in the previous 20 years, up to and around the turn of the century, considerable work was carried out. Unfortunately, the available techniques at the time have limited the potential for the interpretation of outcomes. Additionally, the silo effect, resulting from breaking down the area into investigations of multiple phenotypes and two distinct cofactor families that are seldom considered together, does not foster the level of communication and collaboration necessary to promote efficiency and success.

Future directions

The metabolic overlap between biopterin and folate pathways is now generally accepted. However, given the critical nature of both cofactor families in obligate biosynthetic pathways and the fact that very few recent research papers have focused on this area, we believe further exploration of this nexus is required.^{16,63} In particular, developing and applying new high-performance liquid chromatography-tandem mass spectrometry techniques to quantify individual coenzymes at the one-carbon and individual polyglutamate levels would provide a more complete understanding of what is currently a complex area, which has only been examined using non-specific techniques to date. Genetic variants encoding the various enzymes shown in Figure 1 are also important factors

to evaluate. This will help fill in the gaps in what is currently an extremely under-represented field in the literature.

Conclusions

Folate and biopterin are closely related cofactors that may interact in a manner that enhances biochemical pathways supported by both coenzyme families.

The metabolic interaction between these two cofactor families (Fig. 1) has generated a number of ideas and postulates critical to advancing the biochemical basis of several important and seemingly disparate clinically relevant and/or biologically important phenotypes (melanization, PKU, autism, NTD, affective disorders, vascular disease, etc.). This review provides a brief, integrated overview of this key area, which is under-represented in the literature and would benefit from further exploration. While some of the phenotypes examined may involve folate and biopterin, full explanatory mechanisms remain elusive (e.g., autism and NTD). The degree of *in vivo* reciprocity/overlap between folate and biopterin pathways requires a deeper dive into the basic science and more detailed clinical studies within specific phenotypes. Our understanding is, to some degree, limited by the availability of analytical strategies, with contemporary non-specific methods unlikely to yield particularly useful information. To give context to this statement, over a hundred different folyl coenzymes exist in nature. By developing improved analytical strategies, it should be possible to shed more light on this interesting but enigmatic metabolic nexus than can be achieved with a single non-specific evaluation, such as routine pathology assays for red cell folate.

Acknowledgments

None.

Funding

None.

Conflict of interest

Dr. Mark D. Lucock has been an associate editor of *Exploratory Research and Hypothesis* since June 2016. The author has no other conflicts of interest to note.

Author contributions

Study concept and design (RJL, MDL), analysis and interpretation of data (RJL, MDL), drafting of the manuscript (MDL, RJL), critical revision of the manuscript for important intellectual content (MDL, RJL). Both authors have made significant contributions to this study and have approved the final manuscript.

References

- [1] Himmelreich N, Blau N, Thöny B. Molecular and metabolic bases of tetrahydrobiopterin (BH(4)) deficiencies. *Mol Genet Metab* 2021;133(2):123–136. doi:10.1016/j.ymgme.2021.04.003, PMID:33903016.
- [2] Kaufman S. Some metabolic relationships between biopterin and folate: implications for the “methyl trap hypothesis”. *Neurochem Res* 1991;16(9):1031–1036. doi:10.1007/BF00965847, PMID:1784330.
- [3] Matthews RG, Kaufman S. Characterization of the dihydropterin re-

- ductase activity of pig liver methylenetetrahydrofolate reductase. *J Biol Chem* 1980;255(13):6014–6017. PMID:6967065.
- [4] Miller AL. The methylation, neurotransmitter, and antioxidant connections between folate and depression. *Altern Med Rev* 2008;13(3):216–226. PMID:18950248.
 - [5] Blau N, Thöny B, Cotton RH, Hyland K. Disorders of Tetrahydrobiopterin and Related Biogenic Amines. In: Valle DL, Antonarakis S, Ballabio A, Beaudet AL, Mitchell GA (eds). *The Online Metabolic and Molecular Bases of Inherited Disease*. New York: McGraw-Hill Education; 2019. doi:10.1036/ommbid.388.
 - [6] Werner ER, Blau N, Thöny B. Tetrahydrobiopterin: biochemistry and pathophysiology. *Biochem J* 2011;438(3):397–414. doi:10.1042/BJ20110293, PMID:21867484.
 - [7] Abou-Saleh MT, Anderson DN, Collins J, Hughes K, Cattell RJ, Hamon CG, *et al*. The role of pterins in depression and the effects of antidepressant therapy. *Biol Psychiatry* 1995;38(7):458–463. doi:10.1016/0006-3223(94)00323-u, PMID:8672606.
 - [8] Anderson DN, Abou-Saleh MT, Collins J, Hughes K, Cattell RJ, Hamon CG, *et al*. Pterin metabolism in depression: an extension of the amine hypothesis and possible marker of response to ECT. *Psychol Med* 1992;22(4):863–869. doi:10.1017/s0033291700038435, PMID:1488484.
 - [9] Coppen A, Swade C, Jones SA, Armstrong RA, Blair JA, Leeming RJ. Depression and tetrahydrobiopterin: the folate connection. *J Affect Disord* 1989;16(2-3):103–107. doi:10.1016/0165-0327(89)90062-1, PMID:2522108.
 - [10] Latremoliere A, Costigan M. Combining Human and Rodent Genetics to Identify New Analgesics. *Neurosci Bull* 2018;34(1):143–155. doi:10.1007/s12264-017-0152-z, PMID:28667479.
 - [11] Cronin SJF, Seehus C, Weidinger A, Talbot S, Reissig S, Seifert M, *et al*. The metabolite BH4 controls T cell proliferation in autoimmunity and cancer. *Nature* 2018;563(7732):564–568. doi:10.1038/s41586-018-0701-2, PMID:30405245.
 - [12] Alexander LM, Kutz JL, Kenney WL. Tetrahydrobiopterin increases NO-dependent vasodilation in hypercholesterolemic human skin through eNOS-coupling mechanisms. *Am J Physiol Regul Integr Comp Physiol* 2013;304(2):R164–R169. doi:10.1152/ajpregu.00448.2012, PMID:23193114.
 - [13] Lucock MD, Wild J, Smithells RW, Hartley R. *In vivo* characterization of the absorption and biotransformation of pteroylmonoglutamic acid in man: a model for future studies. *Biochem Med Metab Biol* 1989;42(1):30–42. doi:10.1016/0885-4505(89)90038-8, PMID:2505816.
 - [14] Kelly P, McPartlin J, Goggins M, Weir DG, Scott JM. Unmetabolized folic acid in serum: acute studies in subjects consuming fortified food and supplements. *Am J Clin Nutr* 1997;65(6):1790–1795. doi:10.1093/ajcn/65.6.1790, PMID:9174474.
 - [15] Choi JH, Yates Z, Veysey M, Heo YR, Lucock M. Contemporary issues surrounding folic Acid fortification initiatives. *Prev Nutr Food Sci* 2014;19(4):247–260. doi:10.3746/pnf.2014.19.4.247, PMID:25580388.
 - [16] Shane B. Folate and vitamin B12 metabolism: overview and interaction with riboflavin, vitamin B6, and polymorphisms. *Food Nutr Bull* 2008;29(2 Suppl):S5–S16, discussion S17–9. doi:10.1177/15648265080292S103, PMID:18709878.
 - [17] Sohn KJ, Jang H, Campan M, Weisenberger DJ, Dickhout J, Wang YC, *et al*. The methylenetetrahydrofolate reductase C677T mutation induces cell-specific changes in genomic DNA methylation and uracil misincorporation: a possible molecular basis for the site-specific cancer risk modification. *Int J Cancer* 2009;124(9):1999–2005. doi:10.1002/ijc.24003, PMID:19123462.
 - [18] Blount BC, Mack MM, Wehr CM, MacGregor JT, Hiatt RA, Wang G, *et al*. Folate deficiency causes uracil misincorporation into human DNA and chromosome breakage: implications for cancer and neuronal damage. *Proc Natl Acad Sci U S A* 1997;94(7):3290–3295. doi:10.1073/pnas.94.7.3290, PMID:9096386.
 - [19] Mosharov E, Cranford MR, Banerjee R. The quantitatively important relationship between homocysteine metabolism and glutathione synthesis by the transsulfuration pathway and its regulation by redox changes. *Biochemistry* 2000;39(42):13005–13011. doi:10.1021/bi001088w, PMID:11041866.
 - [20] Lucock MD. Synergy of genes and nutrients: the case of homocysteine. *Curr Opin Clin Nutr Metab Care* 2006;9(6):748–756. doi:10.1097/01.mco.0000247468.18790.1e, PMID:17053430.
 - [21] Hasegawa H, Sawabe K, Nakanishi N, Wakasugi OK. Delivery of exogenous tetrahydrobiopterin (BH4) to cells of target organs: role of salvage pathway and uptake of its precursor in effective elevation of tissue BH4. *Mol Genet Metab* 2005;86(Suppl 1):S2–10. doi:10.1016/j.ymgme.2005.09.002, PMID:16256391.
 - [22] Antoniadou C, Shirodaria C, Warrick N, Cai S, de Bono J, Lee J, *et al*. 5-methyltetrahydrofolate rapidly improves endothelial function and decreases superoxide production in human vessels: effects on vascular tetrahydrobiopterin availability and endothelial nitric oxide synthase coupling. *Circulation* 2006;114(11):1193–1201. doi:10.1161/CIRCULATIONAHA.106.612325, PMID:16940192.
 - [23] Hyndman ME, Verma S, Rosenfeld RJ, Anderson TJ, Parsons HG. Interaction of 5-methyltetrahydrofolate and tetrahydrobiopterin on endothelial function. *Am J Physiol Heart Circ Physiol* 2002;282(6):H2167–H2172. doi:10.1152/ajpheart.00935.2001, PMID:12003825.
 - [24] Shi W, Meininger CJ, Haynes TE, Hatakeyama K, Wu G. Regulation of tetrahydrobiopterin synthesis and bioavailability in endothelial cells. *Cell Biochem Biophys* 2004;41(3):415–434. doi:10.1385/CBB:41:3:415, PMID:15509890.
 - [25] Bottiglieri T, Hyland K, Laundry M, Godfrey P, Carney MW, Toone BK, *et al*. Enhancement of recovery from psychiatric illness by methylfolate. *Lancet* 1990;336(8730):1579–1580. doi:10.1016/0140-6736(90)93355-s, PMID:1979390.
 - [26] Leeming RJ, Hall KS. Folate Metabolism and the Role of Dihydropteridine Reductase (DHPR) deficiency. *Pteridines* 2006;17(4):101–102. doi:10.1515/pteridines.2006.17.4.101.
 - [27] Smith I, Hyland K, Kendall B. Clinical role of pteridine therapy in tetrahydrobiopterin deficiency. *J Inher Metab Dis* 1985;8(Suppl 1):39–45. doi:10.1007/BF01800658, PMID:3930840.
 - [28] Lucock M, Yates Z, Hall K, Leeming R, Rylance G, MacDonald A, *et al*. The impact of phenylketonuria on folate metabolism. *Mol Genet Metab* 2002;76(4):305–312. doi:10.1016/s1096-7192(02)00113-0, PMID:12208135.
 - [29] Leeming RJ, Hall KS. Dihydropteridine Reductase and Folate Metabolism Revisited. *Pteridines* 2010;21(1):84–85. doi:10.1515/pteridines.2010.21.1.84.
 - [30] Pollock RJ, Kaufman S. Dihydrofolate reductase is present in brain. *J Neurochem* 1978;30(1):253–256. doi:10.1111/j.1471-4159.1978.tb07059.x, PMID:621511.
 - [31] Leeming RJ, Blair JA, Melikian V, O’Gorman DJ. Biopterin derivatives in human body fluids and tissues. *J Clin Pathol* 1976;29(5):444–451. doi:10.1136/jcp.29.5.444, PMID:932231.
 - [32] Wolf ST, Stanhewicz AE, Jablonski NG, Kenney WL. Acute ultraviolet radiation exposure attenuates nitric oxide-mediated vasodilation in the cutaneous microvasculature of healthy humans. *J Appl Physiol* (1985) 2018;125(4):1232–1237. doi:10.1152/jappphysiol.00501.2018, PMID:30138076.
 - [33] Blau N, Bonafé L, Thöny B. Tetrahydrobiopterin deficiencies without hyperphenylalaninemia: diagnosis and genetics of dopa-responsive dystonia and sepiapterin reductase deficiency. *Mol Genet Metab* 2001;74(1-2):172–185. doi:10.1006/mgme.2001.3213, PMID:11592814.
 - [34] Bottiglieri T, Hyland K, Laundry M, Godfrey P, Carney MW, Toone BK, *et al*. Folate deficiency, biopterin and monoamine metabolism in depression. *Psychol Med* 1992;22(4):871–876. doi:10.1017/s0033291700038447, PMID:1283223.
 - [35] Smith I, Howells DW, Hyland K. Pteridines and monoamines: relevance to neurological damage. *Postgrad Med J* 1986;62(724):113–123. doi:10.1136/pgmj.62.724.113, PMID:3540926.
 - [36] Crabtree MJ, Channon KM. Synthesis and recycling of tetrahydrobiopterin in endothelial function and vascular disease. *Nitric Oxide* 2011;25(2):81–88. doi:10.1016/j.niox.2011.04.004, PMID:21550412.
 - [37] Dickinson Y, Boehni R, Obeid R, Knapp JP, Moser R, Lewandowski AJ, *et al*. Novel Role of 5-Methyl-(6S)-Tetrahydrofolate in Mediating Endothelial Cell Tetrahydrobiopterin in Pregnancy and Implications for Gestational Hypertension. *Hypertension* 2024;81(9):1910–1923. doi:10.1161/HYPERTENSIONAHA.124.22838, PMID:39041246.
 - [38] Chuaiphichai S, Dickinson Y, Whiteman CAR, Au-Yeung D, McNeill E,

- Channon KM, *et al.* Endothelial cell vasodilator dysfunction mediates progressive pregnancy-induced hypertension in endothelial cell tetrahydrobiopterin deficient mice. *Vascul Pharmacol* 2023;150:107168. doi:10.1016/j.vph.2023.107168, PMID:36966985.
- [39] Liu Z, Dong N, Hui H, Wang Y, Liu F, Xu L, *et al.* Endothelial cell-derived tetrahydrobiopterin prevents aortic valve calcification. *Eur Heart J* 2022;43(17):1652–1664. doi:10.1093/eurheartj/ehac037, PMID:35139535.
- [40] Maletic V, Shelton R, Holmes V. A Review of L-Methylfolate as Adjunctive Therapy in the Treatment of Major Depressive Disorder. *Prim Care Companion CNS Disord* 2023;25(3):22nr03361. doi:10.4088/PCC.22nr03361.
- [41] Zhilyaeva TV, Kasyanov ED, Semennov IV, Rukavishnikov GV, Piatoikina AS, Kostina OV, *et al.* Tetrahydrobiopterin deficiency in schizophrenia: Biochemical and clinical aspects. *J Psychiatr Res* 2022;153:141–148. doi:10.1016/j.jpsychires.2022.07.020, PMID:35816973.
- [42] Chalupsky K, Kračun D, Kanchev I, Bertram K, Görlach A. Folic Acid Promotes Recycling of Tetrahydrobiopterin and Protects Against Hypoxia-Induced Pulmonary Hypertension by Recoupling Endothelial Nitric Oxide Synthase. *Antioxid Redox Signal* 2015;23(14):1076–1091. doi:10.1089/ars.2015.6329, PMID:26414244.
- [43] Lucock M. Vitamin-related phenotypic adaptation to exposomal factors: The folate-vitamin D-exposome triad. *Mol Aspects Med* 2022;87:100944. doi:10.1016/j.mam.2021.100944, PMID:33551238.
- [44] Curtius HC, Kuster T, Matasovic A, Blau N, Dhondt JL. Primapterin, anapterin, and 6-oxo-primapterin, three new 7-substituted pterins identified in a patient with hyperphenylalaninemia. *Biochem Biophys Res Commun* 1988;153(2):715–721. doi:10.1016/s0006-291x(88)81153-7, PMID:3382399.
- [45] Lucock MD, Levene MI, Hartley R. Modulation of potassium evoked secretory function in rat cerebellar slices measured by real time monitoring: evidence of a possible role for methylfolate in cerebral tissue. *Neurochem Res* 1993;18(5):617–623. doi:10.1007/BF00966940, PMID:8474580.
- [46] Leeming RJ, Blair JA, Green A, Raine DN. Biopterin derivatives in normal and phenylketonuric patients after oral loads of L-phenylalanine, L-tyrosine, and L-tryptophan. *Arch Dis Child* 1976;51(10):771–777. doi:10.1136/adc.51.10.771, PMID:1008581.
- [47] Bailey SW, Ayling JE. The extremely slow and variable activity of dihydrofolate reductase in human liver and its implications for high folic acid intake. *Proc Natl Acad Sci U S A* 2009;106(36):15424–15429. doi:10.1073/pnas.0902072106, PMID:19706381.
- [48] Lucock M, Leeming R. Autism, seasonality and the environmental perturbation of epigenome related vitamin levels. *Med Hypotheses* 2013;80(6):750–755. doi:10.1016/j.mehy.2013.03.003, PMID:23566657.
- [49] Frye RE, Huffman LC, Elliott GR. Tetrahydrobiopterin as a novel therapeutic intervention for autism. *Neurotherapeutics* 2010;7(3):241–249. doi:10.1016/j.nurt.2010.05.004, PMID:20643376.
- [50] Adams M, Lucock M, Stuart J, Fardell S, Baker K, Ng X. Preliminary evidence for involvement of the folate gene polymorphism 19bp deletion-DHFR in occurrence of autism. *Neurosci Lett* 2007;422(1):24–29. doi:10.1016/j.neulet.2007.05.025, PMID:17597297.
- [51] James SJ, Melnyk S, Jernigan S, Cleves MA, Halsted CH, Wong DH, *et al.* Metabolic endophenotype and related genotypes are associated with oxidative stress in children with autism. *Am J Med Genet B Neuropsychiatr Genet* 2006;141B(8):947–956. doi:10.1002/ajmg.b.30366, PMID:16917939.
- [52] Boris M, Goldblatt PA, Galanko J, James SJ. Association of MTHFR gene variants with autism. *J Am Physicians Surg* 2004;9(4):106–108.
- [53] Wijemanne S, Jankovic J. Dopa-responsive dystonia—clinical and genetic heterogeneity. *Nat Rev Neurol* 2015;11(7):414–424. doi:10.1038/nrneurol.2015.86, PMID:26160751.
- [54] Czeizel AE. Periconceptional folic acid and multivitamin supplementation for the prevention of neural tube defects and other congenital abnormalities. *Birth Defects Res A Clin Mol Teratol* 2009;85(4):260–268. doi:10.1002/bdra.20563, PMID:19161162.
- [55] Quinn M, Halsey J, Sherliker P, Pan H, Chen Z, Bennett DA, *et al.* Global heterogeneity in folic acid fortification policies and implications for prevention of neural tube defects and stroke: a systematic review. *EClinicalMedicine* 2024;67:102366. doi:10.1016/j.eclinm.2023.102366, PMID:38169713.
- [56] van der Put NM, Steegers-Theunissen RP, Frosst P, Trijbels FJ, Eskes TK, van den Heuvel LP, *et al.* Mutated methylenetetrahydrofolate reductase as a risk factor for spina bifida. *Lancet* 1995;346(8982):1070–1071. doi:10.1016/s0140-6736(95)91743-8, PMID:7564788.
- [57] Lupo PJ, Chapa C, Noursome D, Duhon C, Canfield MA, Shaw GM, *et al.* A GCH1 haplotype and risk of neural tube defects in the National Birth Defects Prevention Study. *Mol Genet Metab* 2012;107(3):592–595. doi:10.1016/j.ymgme.2012.09.020, PMID:23059057.
- [58] Lucock MD, Jones PR, Veysey M, Thota R, Garg M, Furst J, *et al.* Biophysical evidence to support and extend the vitamin D-folate hypothesis as a paradigm for the evolution of human skin pigmentation. *Am J Hum Biol* 2022;34(4):e23667. doi:10.1002/ajhb.23667, PMID:34418235.
- [59] Lucock MD. The evolution of human skin pigmentation: A changing medley of vitamins, genetic variability, and UV radiation during human expansion. *Am J Biol Anthropol* 2023;180(2):252–271. doi:10.1002/ajpa.24564, PMID:36790744.
- [60] Shih BB, Farrar MD, Vail A, Allan D, Chao MR, Hu CW, *et al.* Influence of skin melanisation and ultraviolet radiation on biomarkers of systemic oxidative stress. *Free Radic Biol Med* 2020;160:40–46. doi:10.1016/j.freeradbiomed.2020.07.034, PMID:32768566.
- [61] Selhub J, Miller JW. The pathogenesis of homocysteinemia: interruption of the coordinate regulation by S-adenosylmethionine of the remethylation and transsulfuration of homocysteine. *Am J Clin Nutr* 1992;55(1):131–138. doi:10.1093/ajcn/55.1.131, PMID:1728812.
- [62] Wolf ST, Kenney WL. The vitamin D-folate hypothesis in human vascular health. *Am J Physiol Regul Integr Comp Physiol* 2019;317(3):R491–R501. doi:10.1152/ajpregu.00136.2019, PMID:31314544.
- [63] Longo N. Disorders of biopterin metabolism. *J Inherit Metab Dis* 2009;32(3):333–342. doi:10.1007/s10545-009-1067-2, PMID:19234759.